Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Inflammatory Bowel Diseases

Free Subscription Articles published in Am J Gastroenterol Retrieve available abstracts of 272 articles: HTML format

Single Articles

December 2023
1. BOURGONJE AR, Mian P
   Identifying Phenotypic Determinants of Infliximab Target Concentrations in Inflammatory Bowel Disease: Toward Personalized Evidence-Based Dosing Regimens.
   Am J Gastroenterol. 2023;118:2308-2309.
   PubMed    
   
   
   November 2023
2. KAYAL M, Deepak P, Beniwal-Patel P, Raffals L, et al
   Changes in Therapy Are Not Associated with Increased Remission in Patients with Crohn's Disease of the Pouch.
   Am J Gastroenterol. 2023 Nov 17. doi: 10.14309/ajg.0000000000002599.
   PubMed     Abstract available
   
   
   
3. ANDREW B, Vasudevan A, Srinivasan A
   The Role of Intestinal Ultrasound During Pregnancy in Patients With Inflammatory Bowel Disease.
   Am J Gastroenterol. 2023;118:2096-2097.
   PubMed    
   
   
   
4. BARNES EL, Desai A, Kochhar GS
   The Comparative Effectiveness of Ciprofloxacin and Metronidazole for an Initial Episode of Pouchitis: A Propensity-Matched Study.
   Am J Gastroenterol. 2023;118:1989-1996.
   PubMed     Abstract available
   
   
   
5. SANTIAGO P, Barnes EL, Raffals LE
   Classification and Management of Disorders of the J Pouch.
   Am J Gastroenterol. 2023;118:1931-1939.
   PubMed     Abstract available
   
   
   
6. SACHDEVA K, Agarwal S, Kumar P, Mathew D, et al
   Revised Algorithmic Approach to Differentiate Between Nonspecific and Specific Etiologies of Chronic Terminal Ileitis.
   Am J Gastroenterol. 2023;118:2052-2060.
   PubMed     Abstract available
   
   
   
7. YARUR AJ, Abreu MT, Deepak P, Beniwal-Patel P, et al
   Patients With Inflammatory Bowel Diseases and Higher Visceral Adipose Tissue Burden May Benefit From Higher Infliximab Concentrations to Achieve Remission.
   Am J Gastroenterol. 2023;118:2005-2013.
   PubMed     Abstract available
   
   
   
8. MOHAN BP, Fatima N, Khan SR, Kassab L, et al
   Early Remission With Induction Therapy Predicts Long-Term Remission in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
   Am J Gastroenterol. 2023;118:2084-2087.
   PubMed    
   
   
   
9. KOCHAR B, Mao EJ, Shah SA
   Optimal Dysplasia Detection and Management in IBD: Now and in the Future.
   Am J Gastroenterol. 2023;118:1905-1908.
   PubMed    
   
   
   
10. DUNLEAVY KA, Cross RK, Raffals LE
    Causes, Diagnostic Testing, and Treatment of Residual Symptoms in Patients With IBD With Quiescent Disease.
    Am J Gastroenterol. 2023;118:1909-1914.
    PubMed    
    
    
    October 2023
11. GENERE JR, Ballard DH, Deepak P
    Three-Dimensional Modeling to Guide Interventional Endoscopy in Fibrostenotic Crohn's Disease.
    Am J Gastroenterol. 2023 Oct 13. doi: 10.14309/ajg.0000000000002558.
    PubMed    
    
    
    
12. PHAM JT, Ghusn W, Acosta A, Loftus EV Jr, et al
    Effectiveness and Safety of Antiobesity Medications in Patients With Obesity and Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023 Oct 9. doi: 10.14309/ajg.0000000000002490.
    PubMed     Abstract available
    
    
    
13. DEBRUYN JC, Huynh HQ, Griffiths AM, Jacobson K, et al
    ADALIMUMAB VERSUS INFLIXIMAB IN LUMINAL PEDIATRIC CROHN'S DISEASE: COMPARABLE OUTCOMES IN A PROSPECTIVE MULTICENTER COHORT STUDY.
    Am J Gastroenterol. 2023 Oct 3. doi: 10.14309/ajg.0000000000002552.
    PubMed     Abstract available
    
    
    
14. SHUJA A
    Continuing Medical Education Questions: October 2023.
    Am J Gastroenterol. 2023;118:1742.
    PubMed     Abstract available
    
    
    
15. COELHO-PRABHU N, Lewis JD
    Update on Endoscopic Dysplasia Surveillance in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023;118:1748-1755.
    PubMed     Abstract available
    
    
    September 2023
16. ALSOUD D, Ho J, Sabino J, Ferrante M, et al
    Utility of the Serum-Based Endoscopic Healing Index in Monitoring Therapeutic Response in Ulcerative Colitis.
    Am J Gastroenterol. 2023 Sep 27. doi: 10.14309/ajg.0000000000002518.
    PubMed     Abstract available
    
    
    
17. BAK MTJ, Huinink STB, Erler NS, Bodelier AGL, et al
    Prognostic value of the modified Rutgeerts' score for long-term outcomes after primary ileocecal resection in Crohn's disease.
    Am J Gastroenterol. 2023 Sep 22. doi: 10.14309/ajg.0000000000002509.
    PubMed     Abstract available
    
    
    
18. CAIRNS CA, Cross RK, Khambaty M, Bafford AC, et al
    Monitoring Patients with Inflammatory Bowel Disease at High Risk of Anal Cancer.
    Am J Gastroenterol. 2023 Sep 18. doi: 10.14309/ajg.0000000000002503.
    PubMed     Abstract available
    
    
    
19. SANTIAGO P, Coelho-Prabhu N, Lennon R, Rui S, et al
    Baseline Clinical Factors are Associated with Risk of Complications in Crohn's Disease: Appraisal of the AGA Clinical Care Pathway.
    Am J Gastroenterol. 2023 Sep 15. doi: 10.14309/ajg.0000000000002498.
    PubMed     Abstract available
    
    
    
20. WILKERSON RC
    Continuing Medical Education Questions: September 2023.
    Am J Gastroenterol. 2023;118:1543.
    PubMed     Abstract available
    
    
    
21. KAHN-BOESEL O, Cautha S, Ufere NN, Ananthakrishnan AN, et al
    A Narrative Review of Financial Burden, Distress, and Toxicity of Inflammatory Bowel Diseases in the United States.
    Am J Gastroenterol. 2023;118:1545-1553.
    PubMed     Abstract available
    
    
    August 2023
22. CHANG S, Murphy M, Malter L
    A Review of Available Medical Therapies to Treat Moderate to Severe Inflammatory Bowel Disease in 2023.
    Am J Gastroenterol. 2023 Aug 24. doi: 10.14309/ajg.0000000000002485.
    PubMed     Abstract available
    
    
    
23. LEVARTOVSKY A, Ben-Horin S, Kopylov U, Klang E, et al
    Towards AI-Augmented Clinical Decision Making: An Examination of ChatGPT's Utility in Acute Ulcerative Colitis Presentations.
    Am J Gastroenterol. 2023 Aug 23. doi: 10.14309/ajg.0000000000002483.
    PubMed     Abstract available
    
    
    
24. YANG Y, Ludvigsson JF, Olen O, Sjolander A, et al
    Absolute and relative risks of kidney and urological complications in patients with inflammatory bowel disease.
    Am J Gastroenterol. 2023 Aug 10. doi: 10.14309/ajg.0000000000002473.
    PubMed     Abstract available
    
    
    
25. RAMPERTAB SD
    Continuing Medical Education Questions: August 2023.
    Am J Gastroenterol. 2023;118:1321.
    PubMed     Abstract available
    
    
    
26. BOPARAI ES, Lee JK, Zhu S, Shirazi A, et al
    The Contemporary Probability of Occult Colorectal Cancer in Patients With Colitis-Related Dysplasia Undergoing Colectomy.
    Am J Gastroenterol. 2023;118:1453-1456.
    PubMed     Abstract available
    
    
    July 2023
27. DUBINSKY M, Bleakman AP, Panaccione R, Hibi T, et al
    Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future Directions.
    Am J Gastroenterol. 2023 Jul 12. doi: 10.14309/ajg.0000000000002404.
    PubMed     Abstract available
    
    
    
28. FERNANDEZ C, Gajic Z, Esen E, Remzi F, et al
    Preoperative Risk Factors for Adverse Events in Adults Undergoing Bowel Resection for Inflammatory Bowel Disease: 15-Year Assessment of ACS-NSQIP.
    Am J Gastroenterol. 2023 Jul 7. doi: 10.14309/ajg.0000000000002395.
    PubMed     Abstract available
    
    
    
29. BONFILS L, Sandri AK, Poulsen GJ, Agrawal M, et al
    Medication-wide study: Exploring medication use ten years prior to a diagnosis of inflammatory bowel disease.
    Am J Gastroenterol. 2023 Jul 7. doi: 10.14309/ajg.0000000000002399.
    PubMed     Abstract available
    
    
    
30. BACHOUR SP, Khan MZ, Shah RS, Joseph A, et al
    Anastomotic configuration and temporary diverting ileostomy do not increase risk for anastomotic stricture in postoperative Crohn's disease.
    Am J Gastroenterol. 2023 Jul 7. doi: 10.14309/ajg.0000000000002393.
    PubMed     Abstract available
    
    
    
31. VUYYURU SK, Archer M, Nguyen TM, Beaton M, et al
    Long washout periods between biologics for inflammatory bowel disease clinical trials are unnecessary: A Canadian retrospective cohort study.
    Am J Gastroenterol. 2023 Jul 6. doi: 10.14309/ajg.0000000000002398.
    PubMed     Abstract available
    
    
    
32. BALI AS, Hashash JG, Picco MF, Kinnucan JA, et al
    Electronic Health Record Burden Among Gastroenterology Providers Associated With Subspecialty and Training.
    Am J Gastroenterol. 2023;118:1282-1284.
    PubMed     Abstract available
    
    
    June 2023
33. HU FH, Chen HL
    Low Risk of Lymphoma in Pediatric Patients Treated for Inflammatory Bowel Disease: Need More Evidence.
    Am J Gastroenterol. 2023;118:1101-1102.
    PubMed    
    
    
    
34. DULANEY DT
    Continuing Medical Education Questions: June 2023.
    Am J Gastroenterol. 2023;118:935.
    PubMed     Abstract available
    
    
    
35. DULANEY DT
    Continuing Medical Education Questions: June 2023.
    Am J Gastroenterol. 2023;118:935.
    PubMed     Abstract available
    
    
    May 2023
36. MARKOVINOVIC A, Quan J, Herauf M, Hracs L, et al
    Adverse Events & Serological Responses Following SARS-CoV-2 Vaccination in Individuals with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023 May 22. doi: 10.14309/ajg.0000000000002337.
    PubMed     Abstract available
    
    
    
37. BARNES EL, Zhang X, Long MD, Herfarth HH, et al
    Rate of Colectomy Increases within Twelve Months of Sequential Therapy for Ulcerative Colitis.
    Am J Gastroenterol. 2023 May 22. doi: 10.14309/ajg.0000000000002331.
    PubMed     Abstract available
    
    
    
38. PARIAN AM, Obi M, Fleshner P, Schwartz DA, et al
    Management of Perianal Crohn's Disease - AJG.
    Am J Gastroenterol. 2023 May 19. doi: 10.14309/ajg.0000000000002326.
    PubMed     Abstract available
    
    
    
39. LEY D, Leroyer A, Dupont C, Sarter H, et al
    New therapeutic strategies are associated with a significant decrease in colectomy rate in pediatric ulcerative colitis.
    Am J Gastroenterol. 2023 May 4. doi: 10.14309/ajg.0000000000002316.
    PubMed     Abstract available
    
    
    
40. GOLDOWSKY A, Billings W, Kickel A, Charabaty A, et al
    @MondayNightIBD and the Expanding Gastroenterology Twitterverse: A Study on Continuing Medical Education on #GITwitter.
    Am J Gastroenterol. 2023;118:855-860.
    PubMed     Abstract available
    
    
    April 2023
41. MORTREUX P, Leroyer A, Dupont C, Ley D, et al
    Natural history of anal ulcerations in pediatric-onset Crohn's disease: long-term follow-up of a population-based study.
    Am J Gastroenterol. 2023 Apr 25. doi: 10.14309/ajg.0000000000002301.
    PubMed     Abstract available
    
    
    
42. COHEN-MEKELBURG S, Van T, Berinstein JA, Yu X, et al
    Characteristics of Facilities with Early and Rapid Ustekinumab Adoption for Patients with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023 Apr 25. doi: 10.14309/ajg.0000000000002304.
    PubMed     Abstract available
    
    
    
43. YANG JY, Lund JL, Funk MJ, Hudgens MG, et al
    Utilization of Treat-to-Target Monitoring Colonoscopy after Treatment Initiation in the US-Based Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD).
    Am J Gastroenterol. 2023 Apr 13. doi: 10.14309/ajg.0000000000002294.
    PubMed     Abstract available
    
    
    
44. MARCHEGIANI F, Laurent A, de'Angelis N
    Abdominal mass in a patient with autoimmune hepatitis, ulcerative colitis and BRCA family history - not always what you expect.
    Am J Gastroenterol. 2023 Apr 11. doi: 10.14309/ajg.0000000000002284.
    PubMed    
    
    
    March 2023
45. AHUJA D, Murad MH, Ma C, Jairath V, et al
    Comparative Speed of Early Symptomatic Remission with Advanced Therapies for Moderate-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
    Am J Gastroenterol. 2023 Mar 29. doi: 10.14309/ajg.0000000000002263.
    PubMed     Abstract available
    
    
    
46. OGINO T, Mizushima T, Fujii M, Sekido Y, et al
    Crohn's disease-associated anorectal cancer has a poor prognosis with high local recurrence: a subanalysis of the Nationwide Japanese Study.
    Am J Gastroenterol. 2023 Mar 28. doi: 10.14309/ajg.0000000000002269.
    PubMed     Abstract available
    
    
    
47. ZORZI F, Rubin DT, Cleveland NK, Monteleone G, et al
    Ultrasonographic Transmural healing in Crohn's disease.
    Am J Gastroenterol. 2023 Mar 28. doi: 10.14309/ajg.0000000000002265.
    PubMed     Abstract available
    
    
    
48. FINE LS, Zhu S, Shirazi A, Lee JK, et al
    Increased Risk of Hospitalization, Surgery and Venous Thromboembolism Among Patients with Inflammatory Bowel Disease and Malnutrition in a Large, Community-Based Healthcare System.
    Am J Gastroenterol. 2023 Mar 9. doi: 10.14309/ajg.0000000000002241.
    PubMed     Abstract available
    
    
    February 2023
49. CARD TR, Nakafero G, Grainge MJ, Mallen CD, et al
    Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD.
    Am J Gastroenterol. 2023 Feb 22. doi: 10.14309/ajg.0000000000002205.
    PubMed     Abstract available
    
    
    
50. VUYYURU SK, Rieder F, Solitano V, Nguyen TM, et al
    Patients with Crohn's disease and permanent ileostomy are universally excluded from clinical trials: A systematic review.
    Am J Gastroenterol. 2023 Feb 8. doi: 10.14309/ajg.0000000000002215.
    PubMed     Abstract available
    
    
    
51. MURTHY SK, Benchimol EI
    Low Risk of Lymphoma in Children With IBD Is Reassuring to Clinicians and Families.
    Am J Gastroenterol. 2023;118:261-262.
    PubMed    
    
    
    
52. OTLEY A, Grover Z, Moayyedi P
    Working to Answer the Effectiveness of Nutrition in IBD: Still a Ways to Go.
    Am J Gastroenterol. 2023;118:256-258.
    PubMed     Abstract available
    
    
    
53. CHO JJ, Pak K, Austin RP, Padilla L, et al
    Endometriosis of the Appendix, Cecum, and Ileum Masquerading as Suspected Crohn's Disease.
    Am J Gastroenterol. 2023;118:197.
    PubMed    
    
    
    
54. OLLECH JE, Yanai H, Avni-Biron I, Snir Y, et al
    Fecal Calprotectin and Quality of Life Questionnaires Are Responsive to Change in Pouch Disease Activity After Antibiotic Therapy: Results From a Prospective Clinical Trial.
    Am J Gastroenterol. 2023;118:367-370.
    PubMed     Abstract available
    
    
    
55. JOHNSON AM, Barsky M, Ahmed W, Zullow S, et al
    The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium.
    Am J Gastroenterol. 2023;118:317-328.
    PubMed     Abstract available
    
    
    January 2023
56. KAWASAKI K, Kawatoko S, Yamamoto H, Torisu T, et al
    Sessile Serrated Lesion of the Rectum in Ulcerative Colitis Observed by Image-Enhanced Endoscopy.
    Am J Gastroenterol. 2023 Jan 30. doi: 10.14309/ajg.0000000000002175.
    PubMed    
    
    
    
57. REN T, Yu Y, Wang H, Li F, et al
    Maternal Inflammatory Bowel Disease During Pregnancy and Infectious Disease in Offspring Younger Than 5 Years: A Population-Based Cohort Study.
    Am J Gastroenterol. 2023 Jan 26. doi: 10.14309/ajg.0000000000002179.
    PubMed     Abstract available
    
    
    
58. SUN Y, Yuan S, Chen X, Sun J, et al
    The Contribution of Genetic Risk and Lifestyle Factors in the Development of Adult-Onset Inflammatory Bowel Disease: A Prospective Cohort Study.
    Am J Gastroenterol. 2023 Jan 26. doi: 10.14309/ajg.0000000000002180.
    PubMed     Abstract available
    
    
    
59. LE COSQUER G, Celerier B, Laharie D
    A Rare Cause of Colonic Obstruction in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023 Jan 23. doi: 10.14309/ajg.0000000000002116.
    PubMed    
    
    
    
60. ANDERSON J, Frost S, Keyashian K, Modiano N, et al
    Pentosan Polysulfate-Associated Dysplasia in Patients With Inflammatory Bowel Disease: A Case Series.
    Am J Gastroenterol. 2023 Jan 23. doi: 10.14309/ajg.0000000000002137.
    PubMed     Abstract available
    
    
    
61. LARSEN L, Sandri AK, Fallingborg J, Jacobsen BA, et al
    Has the incidence of inflammatory bowel disease peaked? Evidence from the population-based NorDIBD Cohort 1978-2020.
    Am J Gastroenterol. 2023 Jan 13. doi: 10.14309/ajg.0000000000002187.
    PubMed     Abstract available
    
    
    
62. SEISHIMA R, Okabayashi K, Ikeuchi H, Uchino M, et al
    Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study.
    Am J Gastroenterol. 2023 Jan 9. doi: 10.14309/ajg.0000000000002149.
    PubMed     Abstract available
    
    
    
63. HEUTHORST L, Harbech H, Snijder HJ, Mookhoek A, et al
    Increased Proportion of Colorectal Cancer in Patients With Ulcerative Colitis Undergoing Surgery in the Netherlands.
    Am J Gastroenterol. 2023 Jan 6. doi: 10.14309/ajg.0000000000002099.
    PubMed     Abstract available
    
    
    
64. CHEIFETZ AS, Vande Casteele N, Wang Z, Dubinsky MC, et al
    Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn's Disease: A Post Hoc Analysis of the REACH Trial.
    Am J Gastroenterol. 2023 Jan 5. doi: 10.14309/ajg.0000000000002096.
    PubMed     Abstract available
    
    
    
65. TSE CS, Singh S, Valasek MA, Neill J, et al
    Prevalence and Correlations of Gastrointestinal Symptoms With Endoscopic and Histologic Mucosal Healing in Crohn's Disease.
    Am J Gastroenterol. 2023 Jan 5. doi: 10.14309/ajg.0000000000002122.
    PubMed     Abstract available
    
    
    
66. NARULA N, Wong ECL, Marshall JK, Jairath V, et al
    Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study.
    Am J Gastroenterol. 2023;118:121-128.
    PubMed     Abstract available
    
    
    December 2022
67. AXELRAD JE, Cross RK
    Surveillance for colorectal neoplasia in inflammatory bowel disease: When to stop.
    Am J Gastroenterol. 2022 Dec 29. doi: 10.14309/ajg.0000000000002168.
    PubMed    
    
    
    
68. TAKENAKA K, Kitazume Y, Kawamoto A, Fujii T, et al
    Serum Leucine-Rich alpha2 Glycoprotein: A Novel Biomarker for Transmural Inflammation in Crohn's Disease.
    Am J Gastroenterol. 2022 Dec 27. doi: 10.14309/ajg.0000000000002127.
    PubMed     Abstract available
    
    
    
69. UKASHI O, Kopylov U, Ungar B, Haj-Natour O, et al
    Patency capsule: A novel independent predictor for long-term outcomes among patients with quiescent Crohn's disease.
    Am J Gastroenterol. 2022 Dec 23. doi: 10.14309/ajg.0000000000002118.
    PubMed     Abstract available
    
    
    
70. ACOSTA MB, Fernandez-Clotet A, Mesonero F, Garcia-Alonso FJ, et al
    Long-term outcomes of biological therapy in Crohn's disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU.
    Am J Gastroenterol. 2022 Dec 14. doi: 10.14309/ajg.0000000000002152.
    PubMed     Abstract available
    
    
    
71. CHAPARRO M, Acosta D, Rodriguez C, Mesonero F, et al
    Real-world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness and safety.
    Am J Gastroenterol. 2022 Dec 14. doi: 10.14309/ajg.0000000000002145.
    PubMed     Abstract available
    
    
    
72. MA C, Panaccione R, Xiao Y, Khandelwal Y, et al
    REMIT-UC: Real World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis.
    Am J Gastroenterol. 2022 Dec 8. doi: 10.14309/ajg.0000000000002129.
    PubMed     Abstract available
    
    
    
73. BERENBLUM TOBI C
    Principles for Assessing Quality of Life in Patients With Crohn's Disease.
    Am J Gastroenterol. 2022;117:1952-1953.
    PubMed     Abstract available
    
    
    
74. SHAFI MA
    Continuing Medical Education Questions: December 2022.
    Am J Gastroenterol. 2022;117:1910.
    PubMed     Abstract available
    
    
    November 2022
75. KAPPELMAN MD, Adimadhyam S, Hou L, Wolfe AE, et al
    Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease.
    Am J Gastroenterol. 2022 Nov 23. doi: 10.14309/ajg.0000000000002068.
    PubMed     Abstract available
    
    
    
76. KHAN N, Mahmud N
    COVID-19 Vaccine Effectiveness Against the Omicron Variant in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2022 Nov 23. doi: 10.14309/ajg.0000000000002071.
    PubMed     Abstract available
    
    
    
77. VARMA A, Weinstein J, Seabury J, Rosero S, et al
    Patient-Reported Impact of Symptoms in Crohn's Disease.
    Am J Gastroenterol. 2022 Nov 15. doi: 10.14309/ajg.0000000000001954.
    PubMed     Abstract available
    
    
    
78. BIRCH RJ, Burr N, Subramanian V, Tiernan JP, et al
    Inflammatory Bowel Disease-Associated Colorectal Cancer Epidemiology and Outcomes: An English Population-Based Study.
    Am J Gastroenterol. 2022;117:1858-1870.
    PubMed     Abstract available
    
    
    
79. DUNLEAVY K, Fogwe D, Forde G, Ho M, et al
    A Rare Complication: Postoperative Pyoderma Gangrenosum in Segmental Colitis Associated With Diverticulosis.
    Am J Gastroenterol. 2022;117:1734.
    PubMed    
    
    
    
80. CHENG D, Kochar B, Cai T, Ritchie CS, et al
    Comorbidity Influences the Comparative Safety of Biologic Therapy in Older Adults With Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2022;117:1845-1850.
    PubMed     Abstract available
    
    
    October 2022
81. BERNSTEIN CN, Fisk JD, Walld R, Bolton JM, et al
    Use of Benzodiazepines and Z-Drugs in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2022 Oct 27. pii: 00000434-990000000-00474.
    PubMed     Abstract available
    
    
    
82. FAIRBRASS KM, Guthrie EA, Black CJ, Selinger CP, et al
    Characteristics and Impact of Anxiety and Depression Trajectories in Inflammatory Bowel Disease.: Anxiety and Depression Trajectories in IBD.
    Am J Gastroenterol. 2022 Oct 12. pii: 00000434-990000000-00552.
    PubMed     Abstract available
    
    
    
83. EGBERG MD, Zhang X, Smitherman AB, Kappelman MD, et al
    LOW RISK OF LYMPHOMA IN PEDIATRIC PATIENTS TREATED FOR INFLAMMATORY BOWEL DISEASE.
    Am J Gastroenterol. 2022 Oct 10. pii: 00000434-990000000-00543.
    PubMed     Abstract available
    
    
    
84. DONG J, Ladonne M, Feuerstein JD
    Medicare Patients Face High Out-of-Pocket Costs for Specialty Inflammatory Bowel Disease Medications.
    Am J Gastroenterol. 2022 Oct 10. pii: 00000434-990000000-00549.
    PubMed     Abstract available
    
    
    
85. INAMDAR S
    Continuing Medical Education Questions: October 2022.
    Am J Gastroenterol. 2022;117:1564.
    PubMed     Abstract available
    
    
    
86. SHMIDT E, Dubinsky MC
    Inflammatory Bowel Disease and Pregnancy.
    Am J Gastroenterol. 2022;117.
    PubMed    
    
    
    
87. GU P, Luo J, Kim J, Paul P, et al
    Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
    Am J Gastroenterol. 2022;117:1639-1647.
    PubMed     Abstract available
    
    
    September 2022
88. KASTL A, Weaver KN, Zhang X, Strople JA, et al
    Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease.
    Am J Gastroenterol. 2022 Sep 16. pii: 00000434-990000000-00507.
    PubMed     Abstract available
    
    
    
89. GUPTA A, Kizza JF, Ananthakrishnan AN
    Histologic activity in an endoscopically normal appearing pouch predicts future risk of pouchitis in patients with ulcerative colitis.
    Am J Gastroenterol. 2022 Sep 16. pii: 00000434-990000000-00511.
    PubMed     Abstract available
    
    
    
90. DULANEY DT
    Continuing Medical Education Questions: September 2022.
    Am J Gastroenterol. 2022;117:1407.
    PubMed     Abstract available
    
    
    
91. BOSCHETTI G, Nachury M, Laharie D, Roblin X, et al
    Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAID.
    Am J Gastroenterol. 2022;117:1482-1490.
    PubMed     Abstract available
    
    
    August 2022
92. DANESE S, Ferrante M, Feagan BG, Peyrin-Biroulet L, et al
    Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial.
    Am J Gastroenterol. 2022 Aug 23. pii: 00000434-990000000-00486.
    PubMed     Abstract available
    
    
    
93. COHEN-MEKELBURG S, Van T, Wallace B, Berinstein J, et al
    The association between non-steroidal anti-inflammatory drug use and inflammatory bowel disease exacerbations: a true association or residual bias?
    Am J Gastroenterol. 2022 Aug 12. pii: 00000434-990000000-00457.
    PubMed     Abstract available
    
    
    
94. AGRAWAL M, Allin KH, Iversen AT, Mehandru S, et al
    Early life mebendazole exposure increases the risk of adult-onset ulcerative colitis: a population-based cohort study.
    Am J Gastroenterol. 2022 Aug 12. pii: 00000434-990000000-00466.
    PubMed     Abstract available
    
    
    
95. VAN DEEN WK, Simpson M, Dupuy TP, Khalil C, et al
    Social Media for the Dissemination of Educational Videos About Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2022;117:1320-1323.
    PubMed     Abstract available
    
    
    
96. ONALI S, Pugliese D, Caprioli FA, Orlando A, et al
    An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors.
    Am J Gastroenterol. 2022;117:1279-1287.
    PubMed     Abstract available
    
    
    July 2022
97. BESSISSOW T, Kron CM, Marcus V, Lemieux C, et al
    Impact of Endoscopic and Histologic Activity on Disease Relapse in Ulcerative Colitis.
    Am J Gastroenterol. 2022 Jul 21. pii: 00000434-990000000-00439.
    PubMed     Abstract available
    
    
    
98. LO B, Liu Z, Bendtsen F, Igel C, et al
    High accuracy in classifying endoscopic severity in ulcerative colitis using convolutional neural network.
    Am J Gastroenterol. 2022 Jul 15. pii: 00000434-990000000-00434.
    PubMed     Abstract available
    
    
    
99. ISAACS K, Kane S
    Doctor, What Is the Best Crohn's Therapy?
    Am J Gastroenterol. 2022;117:1041-1043.
    PubMed     Abstract available
    
    
    
100. JAIN A, Bricker J, Kappelman MD, Dotson JL, et al
     Overweight and Obese Status Is Not Associated With Disease Activity for Children and Adolescents With Newly Diagnosed Inflammatory Bowel Disease.
     Am J Gastroenterol. 2022;117:1146-1153.
     PubMed     Abstract available
     
     
     
101. NARULA N, Wong ECL, Dulai PS, Marshall JK, et al
     Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease.
     Am J Gastroenterol. 2022;117:1106-1117.
     PubMed     Abstract available
     
     
     June 2022
102. ALMARIO CV, van Deen WK, Chen M, Gale R, et al
     Interactive Inflammatory Bowel Disease Biologics Decision Aid Does Not Improve Patient Outcomes Over Static Education: Results from a Randomized Trial.
     Am J Gastroenterol. 2022 Jun 10. pii: 00000434-990000000-00406.
     PubMed     Abstract available
     
     
     May 2022
103. MARILD K, Soderling J, Lebwohl B, Green PH, et al
     ASSOCIATION OF CELIAC DISEASE AND INFLAMMATORY BOWEL DISEASE: A NATIONWIDE REGISTER-BASED COHORT STUDY.
     Am J Gastroenterol. 2022 May 25. pii: 00000434-990000000-00380.
     PubMed     Abstract available
     
     
     April 2022
104. KAPLAN HC, Opipari-Arrigan L, Yang J, Schmid CH, et al
     Personalized Research on Diet in Ulcerative Colitis and Crohn's Disease (PRODUCE): A Series of N-of-1 Diet Trials.
     Am J Gastroenterol. 2022 Apr 20. pii: 00000434-990000000-00348.
     PubMed     Abstract available
     
     
     
105. LUTZ M, Hayney MS, Caldera F
     We should not forget about patients with inflammatory bowel disease who received a COVID-19 viral vector vaccine.
     Am J Gastroenterol. 2022 Apr 15. pii: 00000434-990000000-00337.
     PubMed    
     
     
     
106. DULAI PS, Rai V, Raffals LE, Lukin D, et al
     Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel.
     Am J Gastroenterol. 2022 Apr 13. pii: 00000434-990000000-00329.
     PubMed    
     
     
     
107. SASSINE S, Djani L, Cambron-Asselin C, Savoie M, et al
     Risk Factors of Clinical Relapses in Pediatric Luminal Crohn's Disease: A Retrospective Cohort Study.
     Am J Gastroenterol. 2022;117:637-646.
     PubMed     Abstract available
     
     
     March 2022
108. ROLAK S, Caldera F
     The current knowns and unknowns of COVID-19 vaccine induced immunity in patients with inflammatory bowel disease.
     Am J Gastroenterol. 2022 Mar 15. pii: 00000434-990000000-00282.
     PubMed    
     
     
     
109. WINTER RW, Friedman S, Nielsen J, Kjeldsen J, et al
     Infliximab Is Not Associated With a General Long-Term Weight Gain in Patients With Inflammatory Bowel Disease: A Nationwide Study.
     Am J Gastroenterol. 2022 Mar 14. pii: 00000434-990000000-00278.
     PubMed     Abstract available
     
     
     
110. KAPPELMAN MD, Weaver KN, Zhang X, Dai X, et al
     Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases.
     Am J Gastroenterol. 2022;117:462-469.
     PubMed     Abstract available
     
     
     February 2022
111. SNINSKY JA, Barnes EL, Zhang X, Long MD, et al
     Urgency and its association with quality of life and clinical outcomes in ulcerative colitis patients.
     Am J Gastroenterol. 2022 Feb 15. pii: 00000434-990000000-00253.
     PubMed     Abstract available
     
     
     January 2022
112. TSIPOTIS E, Frey S, Connolly C, Werbel WA, et al
     Antibody Response Three Months after Two-Dose SARS-CoV-2 mRNA Vaccination in patients with Inflammatory Bowel Disease.
     Am J Gastroenterol. 2022 Jan 29. pii: 00000434-990000000-00231.
     PubMed     Abstract available
     
     
     
113. HAMADA K, Mankawa N, Yamamoto S
     May-Thurner syndrome in a patient with ulcerative colitis complicated by coronavirus disease 2019.
     Am J Gastroenterol. 2022 Jan 29. pii: 00000434-990000000-00233.
     PubMed    
     
     
     
114. GARRIDO I, Lopes S, Andrade P, Real AC, et al
     Immune Response Induced by SARS-CoV-2 Vaccines in Patients With Inflammatory Bowel Disease Under Biologic Therapy.
     Am J Gastroenterol. 2022 Jan 24. pii: 00000434-990000000-00217.
     PubMed    
     
     
     December 2021
115. MOLLY S, Margaret M, Erin F
     P076 The Role of Dual Biologic Therapy in Inflammatory Bowel Disease.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
116. JARED S, Edward B, Xian Z, Millie L, et al
     P075 Urgency and its Association with Quality of Life and Clinical Outcomes in Ulcerative Colitis Patients.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
117. RAHUL D, Jennifer M, Hannah G, Jessica A, et al
     P074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naive Patients With Ulcerative Colitis.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
118. BENJAMIN S, Kristine P, Kevin T, James M, et al
     P072 Non-invasive Vagal Nerve Stimulation to Treat Crohn Disease and Ulcerative Colitis in Children and Young Adults: A Proof-of-Concept Clinical Trial.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
119. JOSE RL, Jesus LG, Tomas CE, Korely TF, et al
     P063 Prevalence in the Use of Complementary/Alternative Medicine in Patients With Inflammatory Bowel Disease from Centro Medico Nacional 20 de Noviembre.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
120. KORELY TF, Jesus LG, Tomas CE, Rebeca PC, et al
     P061 Impact of Inflammatory Bowel Disease on sleep quality in a Mexican population attended in a referral center.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
121. VIVIANA PI, Jaiber G, Cristian F, Diego J, et al
     P060 Screening Criteria of Inflammatory Bowel Disease: Application in Colombian Patients With Spondyloarthritis.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
122. JULTON TC, Lauren S, Mouhammed S, Adil M, et al
     P058 Impact of Inflammatory Bowel Disease Treatment and Risk of Covid-19 Infection after Full Immunization: A Nationwide Analysis.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
123. CARLOS PA, Tomas CE, Jesus LG, Korely TF, et al
     P057 How Distance Between Residence and Treatment Center Impact the Outcome of Patients With Inflammatory Bowel Disease at CMN 20.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
124. VIVIANA PI, Juan FO, Pablo G, Consuelo RS, et al
     P056 Real life experience with the use of tofacitinib in ulcerative colitis in Colombia: case series.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
125. SANG TC, Sarah A, Yousef E, Joshua T, et al
     P055 Sociodemographic Differences in Fecal Enteropathogen Testing Patterns in Adults Hospitalized for Inflammatory Bowel Disease Flares.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
126. MIKAELL F, Ligia S, Adriana A, Roberto KJ, et al
     P052 National Registration of Patients With Inflammatory Bowel Disease in Brazil on Behalf of GEDIIB.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
127. MARTA F, Tiago LC, Vitor MS, Catia A, et al
     P051 Identifying High-Risk Patients With Acute Severe Ulcerative Colitis: Is the ACE Index Useful?
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
128. VIVIANA PI, Katherin C, Julio A, Maria B, et al
     P050 Oral Inflammatory Changes Associated With Inflammatory Bowel Disease in Spondyloarthritis Associated With Early Endoscopic Findings.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
129. DANIEL S, Marina L, Ana Carolina O, Rodrigo B, et al
     P049 Investigation of Liver Diseases by Ultrasound in Patients With Inflammatory Bowel Disease.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
130. MARINA L, Daniel S, Ana Carolina O, Rodrigo B, et al
     P045 Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD) in a Brazilian public healthcare clinic.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
131. QIAN C, Myrlene S, Nurgul B, Lilla DS, et al
     P043 Resource Utilization and Productivity Loss among Patients with Inflammatory Bowel Disease in Sweden: A Longitudinal Nationwide Population-based Study.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
132. MILLIE L, Raymond C, Jonathan C, Marc P, et al
     P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
133. JEAN-FREDERIC C, Geert D, Peter I, AnnKatrin P, et al
     P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
134. DAVID H, Millie L, Douglas W, Stephen H, et al
     P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
135. BRUCE S, Marc P, Michael S, AnnKatrin P, et al
     P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
136. DAVID R, Remo P, Alison PB, Cem K, et al
     P028 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Patient and Healthcare Professional Perspectives on Experience of Ulcerative Colitis Symptoms.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
137. APAAR D, Khushboo G, Jayesh R, Shesh R, et al
     P027 Brain Fog in Patients With Inflammatory Bowel Disease, and Association With Use of Probiotics.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
138. ADAM S, Nicole L, Heba I, Harini N, et al
     P026 Inflammatory Bowel Disease (IBD) Related Outcomes in Patients Diagnosed With COVID-19.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
139. SIGRID Y, Scott S, Shannon C
     P024 Anorectal Manometry in Patients with Fecal Incontinence After Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease: A Cohort Study.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
140. KEVIN C, Sandra K, Noll R
     P023 Parental Distress in Pediatric Inflammatory Bowel Disease.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
141. VARUN J, Brian B, Esteban F
     P022 Biologic Therapy and Therapeutic Drug Monitoring in Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
142. VITOR MS, Tiago LC, Marta F, Tiago CG, et al
     P020 Proton Pump Inhibitor Therapy: Providing "Acid" Outcomes in Patients With Inflammatory Bowel Disease Under Infliximab Treatment.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
143. IANA G, Randall J, Marc P
     P019 Not All Fecal Calprotectin is Specific for Inflammatory Bowel Disease.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
144. MARIYA Z, Oleg K, Karina N
     P017 Increased Level of Immunoglobulin G in the Development of Adverse Reactions in Patients With Ulcerative Colitis.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
145. RICHARD WY
     P011 Prevalence of Cannabis Use Disorder in Inflammatory Bowel Disease Hospitalizations in the United States and Effect on Length of Stay.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
146. HARTMAN B, Diana H, Casey C
     P009 Assessing the Status Quo: Ulcerative Colitis Monitoring in a Community GI Practice.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
147. OLEG K, Sergey K, Anna K, Albina L, et al
     P006 The Relationship of Histological Remission With the Duration of the Anamnesis Ulcerative Colitis.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
148. OLEG K, Anna K, Albina L, Anait B, et al
     P004 Steroid-Free Remission in Patients With Ulcerative Colitis Receiving Tofacitinib in Real Clinical Practice.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
149. HUI C, Tian F, Lintao D, Xuejie C, et al
     P003 Meat Consumption and All-Cause Mortality in 5763 Inflammatory Bowel Disease Patients: A Prospective Cohort Study.
     Am J Gastroenterol. 2021;116.
     PubMed    
     
     
     
150. STONE M, Morrison M, Forster E
     P076 The Role of Dual Biologic Therapy in Inflammatory Bowel Disease.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
151. SNINSKY J, Barnes E, Zhang X, Long M, et al
     P075 Urgency and its Association with Quality of Life and Clinical Outcomes in Ulcerative Colitis Patients.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
152. DALAL R, Mitri J, Goodrick H, Allegretti J, et al
     P074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naive Patients With Ulcerative Colitis.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
153. SAHN B, Pascuma K, Tracey K, Markowitz J, et al
     P072 Non-invasive Vagal Nerve Stimulation to Treat Crohn Disease and Ulcerative Colitis in Children and Young Adults: A Proof-of-Concept Clinical Trial.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
154. ROMERO LJ, Gomez JL, Espinosa TC, Trujillo de la Fuente K, et al
     P063 Prevalence in the Use of Complementary/Alternative Medicine in Patients With Inflammatory Bowel Disease from Centro Medico Nacional 20 de Noviembre.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
155. TRUJILLO DE LA FUENTE K, Lopez Gomez J, Cortes Espinosa T, Perez-Cabeza de Vaca R, et al
     P061 Impact of Inflammatory Bowel Disease on sleep quality in a Mexican population attended in a referral center.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
156. PARRA IZQUIERDO V, Gutierrez J, Florez C, Jaimes D, et al
     P060 Screening Criteria of Inflammatory Bowel Disease: Application in Colombian Patients With Spondyloarthritis.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
157. PAREDES AMENABAR C, Cortes Espinosa T, Lopez Gomez J, Trujillo de la Fuente K, et al
     P057 How Distance Between Residence and Treatment Center Impact the Outcome of Patients With Inflammatory Bowel Disease at CMN 20.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
158. PARRA IZQUIERDO V, Frias-Ordonez J, Galindo P, Romero-Sanchez C, et al
     P056 Real life experience with the use of tofacitinib in ulcerative colitis in Colombia: case series.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
159. TSE CS, Andrea S, Elfanagely Y, Tanzer J, et al
     P055 Sociodemographic Differences in Fecal Enteropathogen Testing Patterns in Adults Hospitalized for Inflammatory Bowel Disease Flares.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
160. FARIA M, Sassaki L, Andrade A, Kaiser Junior R, et al
     P052 National Registration of Patients With Inflammatory Bowel Disease in Brazil on Behalf of GEDIIB.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
161. FREITAS M, Capela TL, Macedo Silva V, Arieira C, et al
     P051 Identifying High-Risk Patients With Acute Severe Ulcerative Colitis: Is the ACE Index Useful?
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
162. PARRA IZQUIERDO V, Chumacero K, Alvarado J, Buenahora M, et al
     P050 Oral Inflammatory Changes Associated With Inflammatory Bowel Disease in Spondyloarthritis Associated With Early Endoscopic Findings.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
163. SHINTAKU D, Lopes M, de Oliveira AC, Beraldo R, et al
     P049 Investigation of Liver Diseases by Ultrasound in Patients With Inflammatory Bowel Disease.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
164. LOPES M, Shintaku D, de Oliveira AC, Beraldo R, et al
     P045 Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD) in a Brazilian public healthcare clinic.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
165. CAI Q, Sanon M, Batyrbekova N, Di Scala L, et al
     P043 Resource Utilization and Productivity Loss among Patients with Inflammatory Bowel Disease in Sweden: A Longitudinal Nationwide Population-based Study.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
166. LONG M, Cross R, Calkwood J, Pondel M, et al
     P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
167. COLOMBEL JF, D'Haens G, Irving P, Petersen A, et al
     P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
168. HUDESMAN D, Long M, Wolf D, Hanauer S, et al
     P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
169. SANDS B, Pondel M, Silver M, Petersen A, et al
     P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
170. RUBIN D, Panaccione R, Potts Bleakman A, Kayhan C, et al
     P028 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Patient and Healthcare Professional Perspectives on Experience of Ulcerative Colitis Symptoms.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
171. DADLANI A, Gala K, Rai J, Rai S, et al
     P027 Brain Fog in Patients With Inflammatory Bowel Disease, and Association With Use of Probiotics.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
172. YOUNG S, Smukalla S, Chang S
     P024 Anorectal Manometry in Patients with Fecal Incontinence After Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease: A Cohort Study.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
173. CESA K, Kim S, Robert N
     P023 Parental Distress in Pediatric Inflammatory Bowel Disease.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
174. JAIN V, Behm B, Figueroa E
     P022 Biologic Therapy and Therapeutic Drug Monitoring in Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
175. MACEDO SILVA V, Lima Capela T, Freitas M, Curdia Goncalves T, et al
     P020 Proton Pump Inhibitor Therapy: Providing "Acid" Outcomes in Patients With Inflammatory Bowel Disease Under Infliximab Treatment.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
176. GUEORGUIEVA I, Jacobs R, Piper M
     P019 Not All Fecal Calprotectin is Specific for Inflammatory Bowel Disease.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
177. ZVYAGLOVA M, Knyazev O, Noscova K
     P017 Increased Level of Immunoglobulin G in the Development of Adverse Reactions in Patients With Ulcerative Colitis.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
178. WANG YR
     P011 Prevalence of Cannabis Use Disorder in Inflammatory Bowel Disease Hospitalizations in the United States and Effect on Length of Stay.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
179. BRUNT H, Hamer D, Chapman C
     P009 Assessing the Status Quo: Ulcerative Colitis Monitoring in a Community GI Practice.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
180. KNYAZEV O, Khomeriki S, Kagramanova A, Lishchinskaya A, et al
     P006 The Relationship of Histological Remission With the Duration of the Anamnesis Ulcerative Colitis.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
181. KNYAZEV O, Kagramanova A, Lishchinskaya A, Babayan A, et al
     P004 Steroid-Free Remission in Patients With Ulcerative Colitis Receiving Tofacitinib in Real Clinical Practice.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
182. CHEN H, Fu T, Dan L, Chen X, et al
     P003 Meat Consumption and All-Cause Mortality in 5763 Inflammatory Bowel Disease Patients: A Prospective Cohort Study.
     Am J Gastroenterol. 2021;116.
     PubMed     Abstract available
     
     
     
183. DAI C, Jiang M, Huang YH
     The Association Between Serum Infliximab Concentrations and Clinical Outcomes in Fistulizing Crohn's Disease.
     Am J Gastroenterol. 2021;116:2481-2482.
     PubMed    
     
     
     November 2021
184. MELMED GY, Oliver B, Hou JK, Lum D, et al
     Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease.
     Am J Gastroenterol. 2021 Nov 19. pii: 00000434-990000000-00153.
     PubMed     Abstract available
     
     
     
185. CALDERA F, Knutson KL, Saha S, Wald A, et al
     Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls.
     Am J Gastroenterol. 2021 Nov 18. pii: 00000434-990000000-00148.
     PubMed     Abstract available
     
     
     
186. BRUNT H, Chapman JC
     The Inflammatory Bowel Disease-Focused Primary Care Provider: An Addition to the IBD Specialty Medical Home.
     Am J Gastroenterol. 2021 Nov 17. pii: 00000434-990000000-00144.
     PubMed    
     
     
     
187. NGUYEN NH, Martinez I, Atreja A, Sitapati AM, et al
     Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review.
     Am J Gastroenterol. 2021 Nov 9. pii: 00000434-990000000-00141.
     PubMed     Abstract available
     
     
     
188. ALMARIO CV, Kogan L, van Deen WK, Scott FI, et al
     Health Economic Impact of a Multicenter Quality-of-Care Initiative for Reducing Unplanned Healthcare Utilization Among Patients With Inflammatory Bowel Disease.
     Am J Gastroenterol. 2021 Nov 3. pii: 00000434-990000000-00133.
     PubMed     Abstract available
     
     
     
189. CHO JM, Loftus EV Jr, Bruining DH, Chedid VG, et al
     Vulvar Crohn's Disease: Clinical Features and Outcomes.
     Am J Gastroenterol. 2021;116:2296-2299.
     PubMed     Abstract available
     
     
     October 2021
190. LAUBE R, Tran Y, Paramsothy S, Leong RW, et al
     Assisted Reproductive Technology in Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis.
     Am J Gastroenterol. 2021 Oct 25. pii: 00000434-990000000-00131.
     PubMed     Abstract available
     
     
     
191. THAKUR K, Barrett TA
     Social Determinants of Health in Inflammatory Bowel Diseases: Barriers and Opportunities.
     Am J Gastroenterol. 2021;116:2146.
     PubMed    
     
     
     
192. ASHHAB AA, Lee M, Melmed GY
     Extensive Upper Gastrointestinal Fistulization in Crohn's Disease, an Uncommon Cause for a Common Presentation.
     Am J Gastroenterol. 2021;116:1978.
     PubMed    
     
     
     September 2021
193. BATTAT R, Long MD
     Is Proactive Therapeutic Drug Monitoring Ready for the Spotlight in Inflammatory Bowel Disease? Follow the Data.
     Am J Gastroenterol. 2021 Sep 13. pii: 00000434-990000000-00100.
     PubMed     Abstract available
     
     
     August 2021
194. SANGHA M, Roitman I, Sultan K, Swaminath A, et al
     SARS-CoV-2 Immunization in Patients With Inflammatory Bowel Disease May Result in Disease Flares.
     Am J Gastroenterol. 2021 Aug 18. pii: 00000434-990000000-00081.
     PubMed    
     
     
     
195. CHEIFETZ AS, Abreu MT, Afif W, Cross RK, et al
     A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
     Am J Gastroenterol. 2021 Aug 13. pii: 00000434-990000000-00067.
     PubMed     Abstract available
     
     
     
196. RICCIUTO A, Carman N, Benchimol EI, Siddiqui I, et al
     Prospective Evaluation of Endoscopic and Histologic Indices in Pediatric Ulcerative Colitis Using Centralized Review.
     Am J Gastroenterol. 2021 Aug 13. pii: 00000434-990000000-00066.
     PubMed     Abstract available
     
     
     
197. DULAI PS, Jairath V, Narula N, Wong E, et al
     A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease.
     Am J Gastroenterol. 2021;116:1709-1719.
     PubMed     Abstract available
     
     
     July 2021
198. HARRISON N, Humes R, Singla M
     Skip, Stop, Switch, and Spare: Steroid Therapy in Inflammatory Bowel Disease.
     Am J Gastroenterol. 2021 Jul 19. pii: 00000434-990000000-00049.
     PubMed    
     
     
     
199. SCHUMANN M, Sonnenberg E, Siegmund B, Meier K, et al
     A 39-Year-Old Man With Crohn's Disease and a Unclear Rash on His Left Cheek.
     Am J Gastroenterol. 2021;116:1374.
     PubMed    
     
     
     June 2021
200. ABDALLA MI, Levesque BG
     Progress in Corticosteroid Use in the Era of Biologics With Room for Improvement.
     Am J Gastroenterol. 2021;116:1187-1188.
     PubMed     Abstract available
     
     
     
201. TARGOWNIK LE, Bernstein CN, Benchimol EI, Kaplan GG, et al
     Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis.
     Am J Gastroenterol. 2021;116:1284-1293.
     PubMed     Abstract available
     
     
     May 2021
202. DE GIORGI V, Trane L, Silvestri F, Venturi F, et al
     Pyodermatitis-Pyostomatitis Vegetans in Active Inflammatory Bowel Disease.
     Am J Gastroenterol. 2021 May 31. pii: 00000434-900000000-98762.
     PubMed    
     
     
     
203. BOTWIN GJ, Li D, Figueiredo J, Cheng S, et al
     Adverse Events Following SARS-CoV-2 mRNA Vaccination: Among Patients with Inflammatory Bowel Disease.
     Am J Gastroenterol. 2021 May 25. pii: 00000434-900000000-98766.
     PubMed     Abstract available
     
     
     
204. TEICH N, Stallmach A, Bruns T
     Greenspace in Childhood: A New Avenue to Prevent Inflammatory Bowel Disease?
     Am J Gastroenterol. 2021 May 7. pii: 00000434-900000000-98784.
     PubMed    
     
     
     
205. TANG J, Huang Z, Guo H, Ding N, et al
     Online Video Clinic Satisfies the Medical Requirements of Patients with IBD During the COVID-19 Outbreak.
     Am J Gastroenterol. 2021;116:1087.
     PubMed    
     
     
     
206. PAPAMICHAEL K, Vande Casteele N, Jeyarajah J, Jairath V, et al
     Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis.
     Am J Gastroenterol. 2021;116:1007-1014.
     PubMed     Abstract available
     
     
     April 2021
207. KHAN N, Patel D, Xie D, Pernes T, et al
     Are Patients With Inflammatory Bowel Disease at an Increased Risk of Developing SARS-CoV-2 than Patients Without Inflammatory Bowel Disease? Results From a Nationwide Veterans' Affairs Cohort Study.
     Am J Gastroenterol. 2021;116:808-810.
     PubMed     Abstract available
     
     
     
208. KHAN N, Patel D, Trivedi C, Kavani H, et al
     Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients With Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk.
     Am J Gastroenterol. 2021;116:741-747.
     PubMed     Abstract available
     
     
     
209. SONNENBERG A
     Do Forgotten Symptoms Need Treatment?
     Am J Gastroenterol. 2021;116:841-842.
     PubMed    
     
     
     
210. HA C
     The Age-Old Conundrum With Thiopurines: Are the Accumulating Risks Greater Than Benefits?
     Am J Gastroenterol. 2021;116:671-672.
     PubMed     Abstract available
     
     
     March 2021
211. BERNSTEIN CN, Nugent Z, Singh H
     Persistently High Rate of Venous Thromboembolic Disease in Inflammatory Bowel Disease: A Population-Based Study.
     Am J Gastroenterol. 2021 Mar 24. pii: 00000434-900000000-98845.
     PubMed     Abstract available
     
     
     
212. SLATER NR, Loomes DE
     Endoscopic Vacuum-Assisted Wound Closure of a Rectal Perforation in the Setting of Active Ulcerative Colitis.
     Am J Gastroenterol. 2021 Mar 2. pii: 00000434-900000000-98819.
     PubMed    
     
     
     January 2021
213. COELHO-PRABHU N, Kane S
     Does Size Really Matter?
     Am J Gastroenterol. 2021;116:84-85.
     PubMed     Abstract available
     
     
     
214. HAMMOUDI N, Allez M
     Response to Hanzel.
     Am J Gastroenterol. 2021;116:218.
     PubMed    
     
     
     
215. HANZEL J
     A Novel Endoscopic Score for Postoperative Recurrence of Crohn's Disease: More Information Needed.
     Am J Gastroenterol. 2021;116:217-218.
     PubMed    
     
     
     
216. RIVIERE P, D'Haens G, Peyrin-Biroulet L, Baert F, et al
     Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX.
     Am J Gastroenterol. 2021;116:134-141.
     PubMed     Abstract available
     
     
     December 2020
217. LACY BE, Pimentel M, Brenner DM, Chey WD, et al
     ACG Clinical Guideline: Management of Irritable Bowel Syndrome.
     Am J Gastroenterol. 2020 Dec 14. doi: 10.14309/ajg.0000000000001036.
     PubMed     Abstract available
     
     
     
218. KORELITZ BI, Sachar DB, Schneider J
     Full Potential of 6-Mercaptopurine in IBD May Remain Untapped.
     Am J Gastroenterol. 2020;115:2109-2110.
     PubMed    
     
     
     
219. FERNANDA F, Mirella O, Danielle F, Pedro G, et al
     P074 Prevalence and Associated Factors With Non-Adherence to Maintenance Therapy for Ulcerative Colitis in Deep Remission.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
220. PRADEEP KR, Deloshaan S, Dheeraj S, Hadi M, et al
     P070 Outcomes of Acute Severe Ulcerative Colitis in Older Adults.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
221. DELOSHAAN S, Pradeep KR, Dheeraj S, Hadi M, et al
     P069 Admission Steroid Use, Serum Albumin and Endoscopic Severity Predict Intravenous Steroid Failure in Patients With Acute Severe Ulcerative Colitis.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
222. JAQUELINE B, Juliana C, Dos Santos B, Caroline D, et al
     P068 Therapeutic Aspects in Pediatric Inflammatory Bowel Disease - A Multi-Centric Study From Brazil.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
223. FLAVIA P, Cyrla Z, de Souza H, Jessica M, et al
     P066 Hospitalization and Surgery Rates in Patients With Inflammatory Bowel Disease in Brazil: A Time-Trend Analysis.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
224. JENNIFER MO, Megan L, Jean A
     P065 Inflammatory Bowel Disease or Bowel Endometriosis? Two Cases of Large Bowel Obstruction.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
225. JAQUELINE B, Juliana C, Dos Santos Beatriz, Caroline D, et al
     P064 Clinical Aspects of Pediatric Inflammatory Bowel Disease - A Multicentric Study From Brazil.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
226. FABIANA B, Cesar A, Marcio C, Carolina M, et al
     P061 Prophylaxis of Hepatitis B Reactivation and Inflammatory Bowel Disease: A case report.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
227. SVETLANA L, Morris G, Vasiliki S
     P056 Power Calculations in Randomised Controlled Trials of Inflammatory Bowel Disease.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
228. WALAA M, Hisham W, Walid H, Fadi F, et al
     P049 Should the Gallbladder be Empirically Removed at Time of Intestinal Resection in Inflammatory Bowel Disease Patients?
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
229. ERIC J
     P047 Awareness and Impact of Recent AGA Guideline Changes for Moderate to Severe Ulcerative Colitis Patients.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
230. ERIC J
     P046 Though Biosimilar Infliximab Prescribing in Inflammatory Bowel Disease Has Increased, Branded Infliximab Continues to Be Prescribed More Often.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
231. CASEY C, Jenny G, Michelle B, Joe L, et al
     P042 The CONCERT Initiative: Impact of Inflammatory Bowel Disease Care Referral Pathway.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
232. SARA L, Millie L, Uma M
     P040 Indications for Cesarean Section in Pregnant Women with Inflammatory Bowel Disease: Results from the PIANO Registry.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
233. SARA H, David H, Joe Z, Ryan H, et al
     P038 Factors Associated with Impaired Patient-Reported Outcomes and Work Productivity Among Patients with Ulcerative Colitis in Remission.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
234. DAVID P, Caterina O, Christopher A, Gregory AC, et al
     P037 Efficacy and Safety of 1-L NER1006 Bowel Preparation in Patients with Inflammatory Bowel Disease: Analysis of 2 Phase 3 Studies.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
235. CLARA U, Amanda T, Debora T, Giovana C, et al
     P036 Clinical and Psychological Factors Associated with Impaired Body Image in Patients with Inflammatory Bowel Disease.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
236. KAUSTAV S, Austin T, Roman G, Allison M, et al
     P033 Demographic Factors Associated with Successful Telehealth Visits in Inflammatory Bowel Disease Patients.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
237. WILLIAM S, Brian F, Stephen H, Severine V, et al
     P031 Ozanimod in Patients with Moderate-to-Severe Ulcerative Colitis: Long-Term Safety and Efficacy from the Phase 2 TOUCHSTONE Study 4-Year Open-Label Extension.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
238. SILVIO D, Brian F, Stephen H, Igor J, et al
     P030 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Maintenance in the Phase 3 True North Study.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
239. EDWARD B, Harris A, Joe Z, Antoine S, et al
     P027 Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
240. SHINTARO A, Jacob O, Cindy T, Victoria R, et al
     P026 Assessment of Contributing Factors for Fistula Development in Patients with Inflammatory Bowel Disease Treated by Proctocolectomy with Ileal Pouch-Anal Anastomosis.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
241. WILLIAM S, Geert D, Doug W, Stephen H, et al
     P025 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Induction in the Phase 3 True North Study.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
242. GALIYA B, Alisa R, Maria L
     P024 Medical Decision Support System in the Diagnosis of Ulcerative Colitis.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
243. MICHAEL C, Puza S, Benjamin C, Leonardo S, et al
     P021 Characteristics of Patients Treated with Tofacitinib for Ulcerative Colitis in the Real World: Findings from a Large US Claims Database.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
244. SUBRATA G, Geert D, Vipul J, Florian R, et al
     P012 Ozanimod Reduced Fecal Calprotectin Levels in Patients with Ulcerative Colitis in the Phase 3 True North Study.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
245. ROGERIO P, Julio C, Liliana C, Erika B, et al
     P008 Long-Term Effectiveness and Safety of Ustekinumab for The Treatment of Crohn s Disease: A Brazilian Multicentre Real-world Study.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
246. OLEG K, Albina L, Anatoliy K, Anna K, et al
     P005 Overcoming Secondary Loss of Response to Infliximab in Patients With Ulcerative Colitis With the Use of Mesenchymal Stromal Cells.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
247. OLEG K, Anna K, Albina L, Tatyana S, et al
     P002 Frequency and Causes of Prolongation of the Induction Course of Tofacitinib in Patients with Ulcerative Colitis.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     
248. ERNESTO R, Rachel H, Meera L, Pablo P, et al
     P001 North-South Gradient in the Incidence of Pediatric Inflammatory Bowel Disease Along the Atlantic Coast.
     Am J Gastroenterol. 2020;115.
     PubMed    
     
     
     November 2020
249. KHAN N, Patel D, Trivedi C, Kavani H, et al
     Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients With Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk.
     Am J Gastroenterol. 2020 Nov 26. doi: 10.14309/ajg.0000000000001058.
     PubMed     Abstract available
     
     
     
250. ZAVER HB, Ghoz H, Azar A, Alexander LF, et al
     Inferior Mesenteric Arteriovenous Malformation Masquerading as Ulcerative Colitis.
     Am J Gastroenterol. 2020 Nov 10. doi: 10.14309/ajg.0000000000000917.
     PubMed    
     
     
     
251. CHAPARRO M, Gordillo J, Domenech E, Esteve M, et al
     Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial.
     Am J Gastroenterol. 2020;115:1802-1811.
     PubMed     Abstract available
     
     
     
252. BANTY A, Melmed GY
     Improving Hepatitis B Virus Vaccination Responses in Inflammatory Bowel Disease: Does Greater Dose and Greater Frequency Lead to Greater Protection?
     Am J Gastroenterol. 2020;115:1797-1798.
     PubMed     Abstract available
     
     
     
253. LITTLE DHW, Tabatabavakili S, Shaffer SR, Nguyen GC, et al
     Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review.
     Am J Gastroenterol. 2020;115:1768-1774.
     PubMed     Abstract available
     
     
     
254. WINDSOR JW, Underwood FE, Brenner E, Colombel JF, et al
     Data Visualization in the Era of COVID-19: An Interactive Map of the SECURE-IBD Registry.
     Am J Gastroenterol. 2020;115:1923-1924.
     PubMed    
     
     
     
255. CHAPUIS-BIRON C, Kirchgesner J, Pariente B, Bouhnik Y, et al
     Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID.
     Am J Gastroenterol. 2020;115:1812-1820.
     PubMed     Abstract available
     
     
     October 2020
256. BUCHNER AM, Schneider Y, Lichtenstein GR
     Biosimilars in Inflammatory Bowel Disease.
     Am J Gastroenterol. 2020 Oct 27. doi: 10.14309/ajg.0000000000000844.
     PubMed     Abstract available
     
     
     
257. GUBATAN J, Nielsen OH, Levitte S, Juhl CB, et al
     Biologics During Pregnancy in Women With Inflammatory Bowel Disease and Risk of Infantile Infections: A Systematic Review and Meta-Analysis.
     Am J Gastroenterol. 2020 Oct 23. doi: 10.14309/ajg.0000000000000910.
     PubMed     Abstract available
     
     
     
258. KHAN N, Patel D, Xie D, Pernes T, et al
     Are Patients With Inflammatory Bowel Disease at an Increased Risk of Developing SARS-CoV-2 than Patients Without Inflammatory Bowel Disease? Results From a Nationwide Veterans' Affairs Cohort Study.
     Am J Gastroenterol. 2020 Oct 19. doi: 10.14309/ajg.0000000000001012.
     PubMed     Abstract available
     
     
     
259. ELTEN M, Benchimol EI, Fell DB, Kuenzig ME, et al
     Residential Greenspace in Childhood Reduces Risk of Pediatric Inflammatory Bowel Disease: A Population-Based Cohort Study.
     Am J Gastroenterol. 2020 Oct 8. doi: 10.14309/ajg.0000000000000990.
     PubMed     Abstract available
     
     
     
260. FIORINO G, Gilardi D, Radice S, Furfaro F, et al
     Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures.
     Am J Gastroenterol. 2020;115:1719-1721.
     PubMed     Abstract available
     
     
     
261. MANSOOR E, Khoudari G, Abou Saleh M, Elfadawy N, et al
     The Many Faces of COVID-19: Atypical Presentation of COVID-19 in a Patient With Crohn's Disease With Acute Diarrhea Leading to Severe Hypovolemic Hyponatremia-A Case Report.
     Am J Gastroenterol. 2020;115:1730-1731.
     PubMed    
     
     
     
262. GIESE-KIM N, Wu M, Dehghan M, Sceats LA, et al
     Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
     Am J Gastroenterol. 2020;115:1698-1706.
     PubMed     Abstract available
     
     
     September 2020
263. CHAPARRO M, Gordillo J, Domenech E, Esteve M, et al
     Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial.
     Am J Gastroenterol. 2020 Sep 30. doi: 10.14309/ajg.0000000000000926.
     PubMed     Abstract available
     
     
     
264. BANTY A, Melmed GY
     Improving Hepatitis B Virus Vaccination Responses in Inflammatory Bowel Disease: Does Greater Dose and Greater Frequency Lead to Greater Protection?
     Am J Gastroenterol. 2020 Sep 25. doi: 10.14309/ajg.0000000000000921.
     PubMed     Abstract available
     
     
     
265. DALAL RS, Palchaudhuri S, Snider CK, Gitelman Y, et al
     A Multimodal Intervention Using Nonopioid Analgesics Is Associated With Reduced Intravenous Opioid Exposure Among Hospitalized Patients With Inflammatory Bowel Diseases.
     Am J Gastroenterol. 2020;115:1474-1485.
     PubMed     Abstract available
     
     
     
266. QUINN KP, Raffals LE
     An Update on the Medical Management of Inflammatory Pouch Complications.
     Am J Gastroenterol. 2020;115:1439-1450.
     PubMed     Abstract available
     
     
     August 2020
267. NARULA N, Wong ECL, Aruljothy A, Dulai PS, et al
     Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial.
     Am J Gastroenterol. 2020;115:1236-1245.
     PubMed     Abstract available
     
     
     July 2020
268. HAMMOUDI N, Auzolle C, Tran Minh ML, Boschetti G, et al
     Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's Disease.
     Am J Gastroenterol. 2020;115:1084-1093.
     PubMed     Abstract available
     
     
     June 2020
269. ROZICH JJ, Holmer A, Singh S
     Effect of Lifestyle Factors on Outcomes in Patients With Inflammatory Bowel Diseases.
     Am J Gastroenterol. 2020;115:832-840.
     PubMed     Abstract available
     
     
     May 2020
270. BEWTRA M, Lichtenstein GR
     Mongersen and SMAD-7 Inhibition, Not a Lucky 7 for Patients With IBD: When Trial Design Is as Important as Disease Therapy.
     Am J Gastroenterol. 2020;115:687-688.
     PubMed     Abstract available
     
     
     
271. LEE MW, Pourmorady JS, Laine L
     Use of Fecal Occult Blood Testing as a Diagnostic Tool for Clinical Indications: A Systematic Review and Meta-Analysis.
     Am J Gastroenterol. 2020;115:662-670.
     PubMed     Abstract available
     
     
     March 2020
272. SHAH A, Macdonald GA, Morrison M, Holtmann G, et al
     Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework.
     Am J Gastroenterol. 2020 Mar 25. doi: 10.14309/ajg.0000000000000604.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.